Today: October 7, 2015, 2:30 pm

Global leukemia therapeutics market: 10% CAGR between 2012-2016
Global Leukemia Therapeutics Market 2012-2016 - a new market research report on 2014-03-05 15:32:05
The Global Leukemia Therapeutics market is to grow at a CAGR of 10 percent over the period 2012-2016. One of the key factors contributing to this market growth is the significant increase in the number of cancer patients worldwide. The Global Leukemia Therapeutics market has also been witnessing an increase in the number of mergers and acquisitions. However, the delay in cancer diagnosis could pose a challenge to the growth of this market.

There has been increase in the volume of medical tourism in the APAC region. Patients from all around the world are visiting countries such as China and India for various treatments. Healthcare facilities in the APAC region are improving and there is an excellent range of healthcare providers that are offering good-quality treatment for diseases such as cancer and other treatments at low cost. Thus the increasing number of patients going to China and India for cancer treatment is a growing trend that is influencing the healthcare organizations in the region to purchase more therapeutic drugs for the treatment of leukemia.

One of the major factors driving the growth of the Global Leukemia Therapeutics market is the increasing prevalence of cancer patients worldwide. Therapeutic drugs are among the remedies for cancer and hence healthcare organizations across the globe are opting for therapeutic drugs in the treatment of leukemia. However, most of the vendors are focusing on the US market, which is expected to witness a faster growth rate than the global market over the period 2012-2016.

The key vendors dominating this market space are Bristol-Myers Squibb Co., Celgene Corp., GlaxoSmithKline plc, Hoffmann-La Roche Ltd., and Novartis AG. The other vendors mentioned in the report are Ambit Biosciences Inc., ARIAD Pharmaceuticals Inc., Biogen Idec Inc., Cephalon Inc., Clavis Pharma ASA, Eisai Co. Ltd., ERYTECH Pharma SA, Genmab A/S, Genzyme Corp., Pfizer Inc., Sunesis Pharmaceuticals Inc., Talon Therapeutics Inc., and Teva Pharmaceutical Industries Ltd.

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Press Information

Published by
Mike King
London: +44 (0) 203 086 8600

# 521 Words
Related Articles
More From Finance
Credit-Yogi Reveals Special Considerations for Military Members [..]
No one wants to have their vehicle taken back by their banks. It’s a source of stress for the individual [..]
Credit-Yogi Teaches Consumers How To Use HAMP [..]
Be Prepared to Utilize HAMP Lenders do not like to help borrowers prevent foreclosure by accessing the Obama loan modification [..]
Credit-Yogi Informs Military Members Facing Auto Repossession [..]
No one wants to have their vehicle taken back by their banks. It’s a source of stress for the individual [..]
Credit-Yogi .com Teaches Consumers How To Prevent [..]
Want to Halt Vehicle Repossession? Here’s How Sometimes things happen that end up leaving one in a financially strapped position. [..]
Sell Your Phoenix Winter Condo or Townhouse [..]
Most condominium owners or homeowners, in almost every state in the country, are asking the same question: “Should I sell [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.